Work

Present Status of PDT for Lung Cancer using Talaporfin Sodium (Laserphyrin®) in Japan

Year: 2025

Type: article

Abstract: PDT using porfimer sodium (PFS, Photofrin®) is not widely employed partly because of high cost and bulky size of Laser system, and the adverse effects of skin photosensitization in Japan. To resolve these issues, 2nd generation PDT using talaporfin sodium (TPS, Laserphyrin®, Meiji Seika Pharma Ltd., Japan) and a compact-size diode laser were developed. In this presentation, we demonstrate the superiority of TPS compared to PFS for central-type early-stage lung cancer (ESLC), and the usefulness of PDT using TPS for peripheral-type ESLC by data of recent clinical studies.

Source: Photodiagnosis and Photodynamic Therapy

DOI: 10.1016/j.pdpdt.2025.104914

Authors: Kinya Furukawa, Jitsuo Usuda, Harubumi Kato

Institutions: Tokyo Medical University, Nippon Medical School

Language: English

Topic: Photodynamic Therapy Research Studies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,610